Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDETATE CALCIUM DISODIUM vs CUVRIOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
Treatment of acute and chronic lead poisoning (FDA-approved).,Treatment of poisoning by radioactive metals such as plutonium, americium, and curium (off-label).,Treatment of manganese intoxication (off-label).,Treatment of cadmium poisoning (off-label).
Treatment of Wilson disease in patients intolerant to penicillamine,Off-label: treatment of copper overload in other conditions
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
300 mg subcutaneously once daily.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Not metabolized; excreted unchanged in urine, primarily via glomerular filtration.
Metabolized mainly by conjugation and oxidation; minor involvement of CYP450 enzymes.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Negligible (<5%); primarily binds lead in extracellular fluid.
Approximately 90% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg (confined mainly to extracellular space; does not penetrate cells or CNS).
Vd is approximately 0.2–0.3 L/kg, indicating distribution largely confined to plasma and extracellular fluid.
IV or IM: 100% (not absorbed orally).
Not administered orally due to poor absorption; bioavailability by oral route is negligible.
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce dose by 50%. GFR 15-29 m L/min: reduce dose by 75%. GFR < 15 m L/min or dialysis: contraindicated or use with extreme caution at 10-20% of normal dose with monitoring.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No specific guidelines for Child-Pugh based modifications. Use with caution in severe hepatic impairment due to potential for electrolyte disturbances and nephrotoxicity.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; or 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Course: 5 days, may repeat after 2 days rest. For other indications: weight-based dosing similar to adults (50 mg/kg/day).
Safety and efficacy not established in pediatric patients.
Start at low end of dosing range (e.g., 30-40 mg/kg/day) due to age-related decreased renal function. Monitor renal function and electrolytes closely. Avoid use in patients with pre-existing renal impairment without dose reduction.
No specific dose adjustment recommended; clinical studies included a limited number of patients aged ≥65 years, with no overall differences in safety or efficacy observed.
Black box warning for nephrotoxicity, particularly at high doses; may cause fatal renal failure. Avoid in patients with renal disease unless benefits outweigh risks. Monitor renal function closely during therapy.
None
Nephrotoxicity - monitor BUN, creatinine, and urinalysis at baseline and during therapy.,Neurotoxicity - may cause tremors, myoclonus, and seizures, especially with high doses.,Hepatotoxicity - monitor liver function tests.,Arrhythmias - may cause QT prolongation; monitor ECG.,Hypocalcemia - monitor serum calcium levels; may cause tetany.,Use with caution in patients with asthma or allergic history.,Not recommended for prophylaxis of heavy metal poisoning.
Monitor for iron deficiency due to copper chelation,May cause lupus-like syndrome,Monitor liver function tests,Use with caution in patients with renal impairment
Severe renal disease or anuria.,Acute pancreatitis.,Known hypersensitivity to edetate calcium disodium or any component.,Concurrent use with other nephrotoxic drugs.,Pregnancy (only if clearly needed due to risk to fetus from metal poisoning).
Hypersensitivity to trientine or any component,Rheumatoid arthritis (due to potential exacerbation of symptoms),Use in pregnancy only if clearly needed
No specific food restrictions, but maintain adequate hydration. Avoid alcohol due to potential renal effects.
Take CUVRIOR on an empty stomach: at least 1 hour before meals or 2 hours after meals. Avoid high-copper foods such as chocolate, nuts, shellfish, liver, mushrooms, and whole grains. Avoid dairy products and milk within 1 hour of dosing as calcium may reduce absorption. Iron supplements and zinc supplements should be taken at least 2 hours apart from CUVRIOR.
FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; potential for teratogenic effects. Second and third trimesters: Potential fetal toxicity from chelation of essential minerals; avoid use unless necessary.
CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Copper deficiency from aggressive chelation may increase teratogenic risk; therefore, maintaining copper levels within the therapeutic range is critical. First trimester: highest risk for malformations; second and third trimesters: risk of fetal copper deficiency and impaired development if maternal copper is overchelated.
It is not known whether edetate calcium disodium is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio has been reported.
It is unknown whether trientine is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Physiologic increases in renal blood flow and glomerular filtration rate during pregnancy may increase clearance of edetate calcium disodium. Pharmacokinetic data are lacking, but dose adjustments may not be required as dosing is typically based on lead levels and renal function. However, careful monitoring of lead levels and renal function is essential. The drug is contraindicated in patients with severe renal impairment.
Physiologic changes in pregnancy (increased plasma volume, enhanced renal clearance) may reduce trientine concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are lacking. The goal is to maintain copper levels within the therapeutic range; doses may need to be increased to prevent under-chelation, but careful monitoring is essential to avoid over-chelation and copper deficiency. Dose adjustments should be individualized based on serum copper levels and clinical response.
Edetate calcium disodium is used for chelation therapy in heavy metal poisoning, particularly lead. Monitor renal function closely due to risk of nephrotoxicity. Administer via slow IV infusion (over 8-12 hours) after dilution to minimize irritation. Contraindicated in anuria or severe renal impairment. Rapid infusion may cause hypocalcemic tetany; ensure adequate hydration to enhance lead excretion. Use with caution in patients with arrhythmias due to potential electrolyte disturbances.
CUVRIOR (trientine hydrochloride) is a copper-chelating agent used for Wilson disease. Monitor urinary copper excretion and serum free copper (non-ceruloplasmin bound) to guide dosing. Avoid concurrent use with zinc supplements or other chelators due to antagonism. Administer on an empty stomach (1 hour before or 2 hours after meals) and separate from other medications by at least 1 hour. Iron deficiency anemia can occur due to copper depletion; check iron studies periodically. Neurological worsening may occur early in therapy; use lower starting doses in patients with neurological symptoms.
This medication is used to remove lead from your body.,You will receive this drug as an intravenous infusion over several hours.,Drink plenty of fluids during treatment to help flush out lead.,Report any muscle cramps, numbness, or tingling immediately.,Your kidney function and electrolyte levels will be monitored during treatment.,Avoid taking other medications without consulting your doctor, especially those affecting the kidneys.
Take CUVRIOR on an empty stomach, at least 1 hour before or 2 hours after meals.,Separate CUVRIOR from other medications, supplements, or antacids by at least 1 hour.,Do not take CUVRIOR with milk, dairy products, or iron supplements.,Report any new or worsening neurological symptoms, such as tremors, difficulty speaking, or trouble walking, to your doctor immediately.,Regular blood tests are required to monitor copper levels and liver function.,Do not stop taking CUVRIOR abruptly; consult your doctor before making any changes.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDETATE CALCIUM DISODIUM vs CUVRIOR, answered by our medical review team.
EDETATE CALCIUM DISODIUM is a Chelating Agent that works by Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.. CUVRIOR is a Chelating Agent that works by CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDETATE CALCIUM DISODIUM and CUVRIOR depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDETATE CALCIUM DISODIUM is: Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.. The standard adult dose of CUVRIOR is: 300 mg subcutaneously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDETATE CALCIUM DISODIUM and CUVRIOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDETATE CALCIUM DISODIUM is classified as Category C. FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There . CUVRIOR is classified as Category C. CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.